Tregs are notorious for inhibiting anti-tumor responses by penetrating the tumor microenvironment and releasing inhibitory cytokines (TGF-β, IL-13, IL-35), disrupting immune checkpoint-related pathways, and preventing antigen-presenting cell (APC) maturation. The gene discussed is TGFB1; the disease is neoplasm.